Linked Life Data

20099276

Source:http://linkedlifedata.com/resource/pubmed/id/20099276

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2010-8-30
pubmed:abstractText
Cancer cells that develop resistance to chemotherapeutic agents are a major clinical obstacle in the successful treatment of breast cancer. Acquired cancer chemoresistance is a multifactorial phenomenon, involving various mechanisms and processes. Recent studies suggest that chemoresistance may be linked to drug-induced dysregulation of microRNA function. Furthermore, mounting evidence indicates the existence of similarities between drug-resistant and metastatic cancer cells in terms of resistance to apoptosis and enhanced invasiveness. We studied the role of miRNA alterations in the acquisition of cisplatin-resistant phenotype in MCF-7 human breast adenocarcinoma cells. We identified a total of 103 miRNAs that were overexpressed or underexpressed (46 upregulated and 57 downregulated) in MCF-7 cells resistant to cisplatin. These differentially expressed miRNAs are involved in the control of cell signaling, cell survival, DNA methylation and invasiveness. The most significantly dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c. Furthermore, we demonstrated that miR-345 and miR-7 target the human multidrug resistance-associated protein 1. These results suggest that dysregulated miRNA expression may underlie the abnormal functioning of critical cellular processes associated with the cisplatin-resistant phenotype.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1097-0215
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
127
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1785-94
pubmed:meshHeading
pubmed-meshheading:20099276-Antineoplastic Agents, pubmed-meshheading:20099276-Blotting, Western, pubmed-meshheading:20099276-Breast Neoplasms, pubmed-meshheading:20099276-Cisplatin, pubmed-meshheading:20099276-Drug Resistance, Neoplasm, pubmed-meshheading:20099276-Female, pubmed-meshheading:20099276-Gene Expression Profiling, pubmed-meshheading:20099276-Humans, pubmed-meshheading:20099276-Luciferases, pubmed-meshheading:20099276-MicroRNAs, pubmed-meshheading:20099276-Multidrug Resistance-Associated Proteins, pubmed-meshheading:20099276-Oligonucleotide Array Sequence Analysis, pubmed-meshheading:20099276-RNA, Messenger, pubmed-meshheading:20099276-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:20099276-Tumor Cells, Cultured, pubmed-meshheading:20099276-Tumor Markers, Biological
pubmed:year
2010
pubmed:articleTitle
Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.
pubmed:affiliation
Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, AR 72079, USA. igor.pogribny@fda.hhs.gov
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't